Role  ||| S:0 E:5 ||| NN
of  ||| S:5 E:8 ||| IN
health  ||| S:8 E:15 ||| NN
insurance  ||| S:15 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
financing  ||| S:28 E:38 ||| NN
vaccinations  ||| S:38 E:51 ||| NN
for  ||| S:51 E:55 ||| IN
children  ||| S:55 E:64 ||| NNS
and  ||| S:64 E:68 ||| CC
adolescents  ||| S:68 E:80 ||| NNS
in  ||| S:80 E:83 ||| IN
the  ||| S:83 E:87 ||| DT
United  ||| S:87 E:94 ||| NNP
States  ||| S:94 E:101 ||| NNPS
The  ||| S:101 E:105 ||| DT
goal  ||| S:105 E:110 ||| NN
was  ||| S:110 E:114 ||| VBD
to  ||| S:114 E:117 ||| TO
elicit  ||| S:117 E:124 ||| VB
perspectives  ||| S:124 E:137 ||| VBN
of  ||| S:137 E:140 ||| IN
selected  ||| S:140 E:149 ||| JJ
health  ||| S:149 E:156 ||| NN
insurance  ||| S:156 E:166 ||| NN
plan  ||| S:166 E:171 ||| NN
medical  ||| S:171 E:179 ||| JJ
or  ||| S:179 E:182 ||| CC
quality  ||| S:182 E:190 ||| NN
improvement  ||| S:190 E:202 ||| NN
directors  ||| S:202 E:212 ||| NNS
regarding  ||| S:212 E:222 ||| VBG
factors  ||| S:222 E:230 ||| NNS
related  ||| S:230 E:238 ||| VBN
to  ||| S:238 E:241 ||| TO
coverage  ||| S:241 E:250 ||| NN
and  ||| S:250 E:254 ||| CC
reimbursement  ||| S:254 E:268 ||| NN
and  ||| S:268 E:272 ||| CC
perceptions  ||| S:272 E:284 ||| NNS
of  ||| S:284 E:287 ||| IN
financing  ||| S:287 E:297 ||| NN
as  ||| S:297 E:300 ||| IN
a  ||| S:300 E:302 ||| DT
barrier  ||| S:302 E:310 ||| NN
to  ||| S:310 E:313 ||| TO
child  ||| S:313 E:319 ||| NN
and  ||| S:319 E:323 ||| CC
adolescent  ||| S:323 E:334 ||| JJ
immunization ||| S:334 E:346 ||| NN
.  ||| S:346 E:348 ||| .
Medical  ||| S:348 E:356 ||| NNP
or  ||| S:356 E:359 ||| CC
quality  ||| S:359 E:367 ||| NN
improvement  ||| S:367 E:379 ||| NN
directors  ||| S:379 E:389 ||| NNS
from  ||| S:389 E:394 ||| IN
20  ||| S:394 E:397 ||| CD
plans  ||| S:397 E:403 ||| NNS
selected  ||| S:403 E:412 ||| VBN
by  ||| S:412 E:415 ||| IN
America ||| S:415 E:422 ||| NNP
's  ||| S:422 E:425 ||| POS
Health  ||| S:425 E:432 ||| NNP
Insurance  ||| S:432 E:442 ||| NNP
Plans  ||| S:442 E:448 ||| NNP
were  ||| S:448 E:453 ||| VBD
invited  ||| S:453 E:461 ||| VBN
to  ||| S:461 E:464 ||| TO
complete  ||| S:464 E:473 ||| VB
an  ||| S:473 E:476 ||| DT
online  ||| S:476 E:483 ||| JJ
survey  ||| S:483 E:490 ||| NN
in  ||| S:490 E:493 ||| IN
July  ||| S:493 E:498 ||| NNP
2007 ||| S:498 E:502 ||| CD
.  ||| S:502 E:504 ||| .
Respondents  ||| S:504 E:516 ||| NNS
who  ||| S:516 E:520 ||| WP
agreed  ||| S:520 E:527 ||| VBD
to  ||| S:527 E:530 ||| TO
follow-up  ||| S:530 E:540 ||| JJ
interviews  ||| S:540 E:551 ||| NNS
were  ||| S:551 E:556 ||| VBD
invited  ||| S:556 E:564 ||| VBN
to  ||| S:564 E:567 ||| TO
participate  ||| S:567 E:579 ||| VB
in  ||| S:579 E:582 ||| IN
telephone  ||| S:582 E:592 ||| NN
interviews  ||| S:592 E:603 ||| NNS
conducted  ||| S:603 E:613 ||| VBN
by  ||| S:613 E:616 ||| IN
Centers  ||| S:616 E:624 ||| NNPS
for  ||| S:624 E:628 ||| IN
Disease  ||| S:628 E:636 ||| NNP
Control  ||| S:636 E:644 ||| NNP
and  ||| S:644 E:648 ||| CC
Prevention  ||| S:648 E:659 ||| NNP
staff  ||| S:659 E:665 ||| NN
members  ||| S:665 E:673 ||| NNS
in  ||| S:673 E:676 ||| IN
August  ||| S:676 E:683 ||| NNP
2007 ||| S:683 E:687 ||| CD
.  ||| S:687 E:689 ||| .
Fifteen  ||| S:689 E:697 ||| JJ
plans  ||| S:697 E:703 ||| NNS
( ||| S:703 E:704 ||| -LRB-
representing  ||| S:704 E:717 ||| VBG
> ||| S:717 E:718 ||| CD
67  ||| S:718 E:721 ||| CD
million  ||| S:721 E:729 ||| CD
enrollees ||| S:729 E:738 ||| CD
)  ||| S:738 E:740 ||| -RRB-
responded  ||| S:740 E:750 ||| VBD
to  ||| S:750 E:753 ||| TO
the  ||| S:753 E:757 ||| DT
online  ||| S:757 E:764 ||| JJ
survey ||| S:764 E:770 ||| NN
.  ||| S:770 E:772 ||| .
All  ||| S:772 E:776 ||| DT
respondents  ||| S:776 E:788 ||| NNS
covered  ||| S:788 E:796 ||| VBN
all  ||| S:796 E:800 ||| DT
Advisory  ||| S:800 E:809 ||| NNP
Committee  ||| S:809 E:819 ||| NNP
on  ||| S:819 E:822 ||| IN
Immunization  ||| S:822 E:835 ||| NNP
Practices-recommended  ||| S:835 E:857 ||| JJ
child  ||| S:857 E:863 ||| NN
and  ||| S:863 E:867 ||| CC
adolescent  ||| S:867 E:878 ||| JJ
vaccines  ||| S:878 E:887 ||| NNS
in  ||| S:887 E:890 ||| IN
all  ||| S:890 E:894 ||| DT
or  ||| S:894 E:897 ||| CC
most  ||| S:897 E:902 ||| JJS
products ||| S:902 E:910 ||| NNS
.  ||| S:910 E:912 ||| .
Advisory  ||| S:912 E:921 ||| NNP
Committee  ||| S:921 E:931 ||| NNP
on  ||| S:931 E:934 ||| IN
Immunization  ||| S:934 E:947 ||| NNP
Practices  ||| S:947 E:957 ||| NNPS
recommendations  ||| S:957 E:973 ||| NNS
were  ||| S:973 E:978 ||| VBD
the  ||| S:978 E:982 ||| DT
most  ||| S:982 E:987 ||| RBS
commonly  ||| S:987 E:996 ||| RB
cited  ||| S:996 E:1002 ||| VBN
criteria  ||| S:1002 E:1011 ||| NNS
for  ||| S:1011 E:1015 ||| IN
coverage  ||| S:1015 E:1024 ||| NN
decisions  ||| S:1024 E:1034 ||| NNS
( ||| S:1034 E:1035 ||| -LRB-
86.7 ||| S:1035 E:1039 ||| NNP
% ||| S:1039 E:1040 ||| NN
)  ||| S:1040 E:1042 ||| -RRB-
and  ||| S:1042 E:1046 ||| CC
coverage  ||| S:1046 E:1055 ||| NN
modifications  ||| S:1055 E:1069 ||| NNS
( ||| S:1069 E:1070 ||| -LRB-
100 ||| S:1070 E:1073 ||| CD
% ||| S:1073 E:1074 ||| NN
) ||| S:1074 E:1075 ||| -RRB-
.  ||| S:1075 E:1077 ||| .
Factors  ||| S:1077 E:1085 ||| NNS
affecting  ||| S:1085 E:1095 ||| VBG
reimbursement  ||| S:1095 E:1109 ||| NN
that  ||| S:1109 E:1114 ||| WDT
were  ||| S:1114 E:1119 ||| VBD
cited  ||| S:1119 E:1125 ||| VBN
most  ||| S:1125 E:1130 ||| RBS
often  ||| S:1130 E:1136 ||| RB
were  ||| S:1136 E:1141 ||| VBD
manufacturer ||| S:1141 E:1153 ||| NN
's  ||| S:1153 E:1156 ||| POS
vaccine  ||| S:1156 E:1164 ||| NN
price  ||| S:1164 E:1170 ||| NN
( ||| S:1170 E:1171 ||| -LRB-
80 ||| S:1171 E:1173 ||| CD
% ||| S:1173 E:1174 ||| NN
)  ||| S:1174 E:1176 ||| -RRB-
and  ||| S:1176 E:1180 ||| CC
physician  ||| S:1180 E:1190 ||| NN
feedback  ||| S:1190 E:1199 ||| NNS
( ||| S:1199 E:1200 ||| -LRB-
53.3 ||| S:1200 E:1204 ||| CD
% ||| S:1204 E:1205 ||| NN
) ||| S:1205 E:1206 ||| -RRB-
.  ||| S:1206 E:1208 ||| .
In  ||| S:1208 E:1211 ||| IN
follow-up  ||| S:1211 E:1221 ||| JJ
interviews  ||| S:1221 E:1232 ||| NNS
with  ||| S:1232 E:1237 ||| IN
10  ||| S:1237 E:1240 ||| CD
self-selected  ||| S:1240 E:1254 ||| JJ
respondents ||| S:1254 E:1265 ||| NNS
,  ||| S:1265 E:1267 ||| ,
manufacturer ||| S:1267 E:1279 ||| NN
's  ||| S:1279 E:1282 ||| POS
price  ||| S:1282 E:1288 ||| NN
( ||| S:1288 E:1289 ||| -LRB-
7  ||| S:1289 E:1291 ||| CD
of  ||| S:1291 E:1294 ||| IN
10  ||| S:1294 E:1297 ||| CD
plans ||| S:1297 E:1302 ||| NNS
)  ||| S:1302 E:1304 ||| -RRB-
and  ||| S:1304 E:1308 ||| CC
physician  ||| S:1308 E:1318 ||| NN
feedback  ||| S:1318 E:1327 ||| NNS
( ||| S:1327 E:1328 ||| -LRB-
4  ||| S:1328 E:1330 ||| CD
of  ||| S:1330 E:1333 ||| IN
10  ||| S:1333 E:1336 ||| CD
plans ||| S:1336 E:1341 ||| NNS
)  ||| S:1341 E:1343 ||| -RRB-
were  ||| S:1343 E:1348 ||| VBD
identified  ||| S:1348 E:1359 ||| VBN
as  ||| S:1359 E:1362 ||| IN
the  ||| S:1362 E:1366 ||| DT
most-important  ||| S:1366 E:1381 ||| JJ
factors  ||| S:1381 E:1389 ||| NNS
affecting  ||| S:1389 E:1399 ||| VBG
reimbursement ||| S:1399 E:1412 ||| NN
.  ||| S:1412 E:1414 ||| .
Respondents  ||| S:1414 E:1426 ||| NNS
said  ||| S:1426 E:1431 ||| VBD
that  ||| S:1431 E:1436 ||| DT
reimbursement  ||| S:1436 E:1450 ||| NN
delays  ||| S:1450 E:1457 ||| NNS
were  ||| S:1457 E:1462 ||| VBD
most  ||| S:1462 E:1467 ||| RBS
commonly  ||| S:1467 E:1476 ||| RB
attributable  ||| S:1476 E:1489 ||| JJ
to  ||| S:1489 E:1492 ||| TO
providers ||| S:1492 E:1501 ||| NNS
'  ||| S:1501 E:1503 ||| POS
claim  ||| S:1503 E:1509 ||| NN
submission  ||| S:1509 E:1520 ||| NN
errors  ||| S:1520 E:1527 ||| NNS
or  ||| S:1527 E:1530 ||| CC
patient  ||| S:1530 E:1538 ||| JJ
ineligibility ||| S:1538 E:1551 ||| NN
.  ||| S:1551 E:1553 ||| .
Some  ||| S:1553 E:1558 ||| DT
respondents  ||| S:1558 E:1570 ||| NNS
thought  ||| S:1570 E:1578 ||| VBD
that  ||| S:1578 E:1583 ||| DT
vaccine  ||| S:1583 E:1591 ||| NN
financing  ||| S:1591 E:1601 ||| NN
was  ||| S:1601 E:1605 ||| VBD
a  ||| S:1605 E:1607 ||| DT
barrier  ||| S:1607 E:1615 ||| NN
( ||| S:1615 E:1616 ||| -LRB-
4  ||| S:1616 E:1618 ||| CD
of  ||| S:1618 E:1621 ||| IN
10  ||| S:1621 E:1624 ||| CD
plans ||| S:1624 E:1629 ||| NNS
)  ||| S:1629 E:1631 ||| -RRB-
or  ||| S:1631 E:1634 ||| CC
somewhat  ||| S:1634 E:1643 ||| RB
a  ||| S:1643 E:1645 ||| DT
barrier  ||| S:1645 E:1653 ||| NN
( ||| S:1653 E:1654 ||| -LRB-
2  ||| S:1654 E:1656 ||| CD
of  ||| S:1656 E:1659 ||| IN
10  ||| S:1659 E:1662 ||| CD
plans ||| S:1662 E:1667 ||| NNS
)  ||| S:1667 E:1669 ||| -RRB-
to  ||| S:1669 E:1672 ||| TO
providing  ||| S:1672 E:1682 ||| VBG
immunizations ||| S:1682 E:1695 ||| NNS
;  ||| S:1695 E:1697 ||| :
others  ||| S:1697 E:1704 ||| NNS
( ||| S:1704 E:1705 ||| -LRB-
4  ||| S:1705 E:1707 ||| CD
of  ||| S:1707 E:1710 ||| IN
10  ||| S:1710 E:1713 ||| CD
plans ||| S:1713 E:1718 ||| NNS
)  ||| S:1718 E:1720 ||| -RRB-
did  ||| S:1720 E:1724 ||| VBD
not ||| S:1724 E:1727 ||| RB
.  ||| S:1727 E:1729 ||| .
Although  ||| S:1729 E:1738 ||| IN
these  ||| S:1738 E:1744 ||| DT
data  ||| S:1744 E:1749 ||| NNS
suggest  ||| S:1749 E:1757 ||| VBP
that  ||| S:1757 E:1762 ||| DT
health  ||| S:1762 E:1769 ||| NN
insurance  ||| S:1769 E:1779 ||| NN
coverage  ||| S:1779 E:1788 ||| NN
for  ||| S:1788 E:1792 ||| IN
recommended  ||| S:1792 E:1804 ||| JJ
vaccines  ||| S:1804 E:1813 ||| NN
is  ||| S:1813 E:1816 ||| VBZ
high ||| S:1816 E:1820 ||| JJ
,  ||| S:1820 E:1822 ||| ,
coverage  ||| S:1822 E:1831 ||| NN
is  ||| S:1831 E:1834 ||| VBZ
not  ||| S:1834 E:1838 ||| RB
universal  ||| S:1838 E:1848 ||| JJ
across  ||| S:1848 E:1855 ||| IN
all  ||| S:1855 E:1859 ||| DT
products  ||| S:1859 E:1868 ||| NNS
offered ||| S:1868 E:1875 ||| VBD
.  ||| S:1875 E:1877 ||| .
